allergic to doxycycline

FILE PHOTO: A medical staff member walks with a COVID-19 patient at Nurse Isabel Zendal new pandemic hospital amid the coronavirus disease (COVID-19) outbreak in Madrid, Spain, January 29, 2021. REUTERS/Sergio Perez

(Reuters) – A commonly used asthma treatment could cut the need to hospitalize COVID-19 patients if the medicine is given within seven days of symptoms appearing, stop taking coumadin British researchers said on Tuesday.

Budesonide, sold under the brand name Pulmicort by AstraZeneca Plc and also used for treating smoker’s lung, reduced the time needed for patients to recover from COVID-19 as well when given in the inhaled form, the University of Oxford said. (bit.ly/3q40g1W)

Source: Read Full Article